ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, th...
| Publicado en: | Acta Radiologica Vol. 61; no. 3; pp. 404 - 414 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
Mar2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142085570&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 142085570 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02841851 1XG jtl: Acta Radiologica issn: 02841851 maglogo: Y pubinfo: dt: Mar2020 vid: 61 iid: 3 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 142085570 142085570 NLM31357873 10.1177/0284185119864842 NLM31357873 142085570 ppf: 404 ppct: 10 formats: tig: atl: ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma. aug: au: Asenjo García, Beatriz Navarro Guirado, Félix Nagib Raya, Fátima Vidal Denis, María Bravo Rodríguez, Francisco Galán Montenegro, Pedro affil: Department of Radiology, Regional University Hospital of Málaga, Spain sug: subj: Neoplasm Recurrence, Local Glioma Brain Neoplasms Patient Selection Glioma Drug Therapy Magnetic Resonance Imaging Methods Pilot Studies Retrospective Design Neoplasm Recurrence, Local Drug Therapy Brain Neoplasms Drug Therapy Angiogenesis Inhibitors Therapeutic Use Brain Questionnaires ab: Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, the need to identify a biomarker to classify subgroups of potential responders has increased. Purpose: To investigate the feasibility of using apparent diffusion coefficient as a predictor of the response of recurrent high-grade gliomas to bevacizumab or classifier for patients showing better response. Material and Methods: This retrospective study analyzed magnetic resonance images obtained from 39 patients at the time of high-grade glioma progression who were treated using bevacizumab. The apparent diffusion coefficient maps were quantified and modelled as a mixture of Gaussian functions. The correlation of their descriptors and the time to second progression was studied. Log-rank tests were performed to determine the power of these descriptors as the classifiers for patients exhibiting better survival. Results: None of the descriptors showed correlation with time to second progression (r < 0.35) but several of them stratified subgroups showing a better time to second progression passing log-rank tests (P < 0.02). Conclusion: Apparent diffusion coefficient cannot be used to predict the time to second progression of recurrent high-grade gliomas treated with bevacizumab, but it can stratify groups with better time to second progression distributions. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|